1. Home
  2. KNSA vs CCS Comparison

KNSA vs CCS Comparison

Compare KNSA & CCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • CCS
  • Stock Information
  • Founded
  • KNSA 2015
  • CCS 2000
  • Country
  • KNSA United Kingdom
  • CCS United States
  • Employees
  • KNSA N/A
  • CCS N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • CCS Homebuilding
  • Sector
  • KNSA Health Care
  • CCS Consumer Discretionary
  • Exchange
  • KNSA Nasdaq
  • CCS Nasdaq
  • Market Cap
  • KNSA 1.9B
  • CCS 1.6B
  • IPO Year
  • KNSA 2018
  • CCS 2014
  • Fundamental
  • Price
  • KNSA $27.36
  • CCS $51.86
  • Analyst Decision
  • KNSA Strong Buy
  • CCS Buy
  • Analyst Count
  • KNSA 5
  • CCS 4
  • Target Price
  • KNSA $38.80
  • CCS $101.33
  • AVG Volume (30 Days)
  • KNSA 474.9K
  • CCS 417.8K
  • Earning Date
  • KNSA 07-22-2025
  • CCS 07-23-2025
  • Dividend Yield
  • KNSA N/A
  • CCS 2.24%
  • EPS Growth
  • KNSA N/A
  • CCS 7.67
  • EPS
  • KNSA N/A
  • CCS 9.70
  • Revenue
  • KNSA $481,166,000.00
  • CCS $4,352,977,000.00
  • Revenue This Year
  • KNSA $37.21
  • CCS N/A
  • Revenue Next Year
  • KNSA $5.32
  • CCS $4.98
  • P/E Ratio
  • KNSA N/A
  • CCS $5.35
  • Revenue Growth
  • KNSA 59.45
  • CCS 11.97
  • 52 Week Low
  • KNSA $17.38
  • CCS $51.07
  • 52 Week High
  • KNSA $28.56
  • CCS $108.42
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 62.48
  • CCS 38.40
  • Support Level
  • KNSA $26.28
  • CCS $51.07
  • Resistance Level
  • KNSA $27.90
  • CCS $55.30
  • Average True Range (ATR)
  • KNSA 0.99
  • CCS 1.75
  • MACD
  • KNSA -0.07
  • CCS 0.11
  • Stochastic Oscillator
  • KNSA 82.30
  • CCS 10.91

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About CCS Century Communities Inc.

Century Communities Inc is engaged in the development, design, construction, marketing, and selling of single-family attached and detached homes. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its sales representatives and independent real estate brokers. The company generates the majority of its revenue from the Mountain segment.

Share on Social Networks: